RxDoctor Payments Data

Jennifer Schaeffer

Family · Punta Gorda, FLNPI 1255608493

Payments from drug & device makers

$7,819in general payments, 2019–2025

Across 434 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$975
  • AbbVie$875
  • Pfizer$865
  • Astellas Pharma US Inc$714
  • Merck$651
  • GSK$605
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,44595%
  • Education$3735%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,819 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$272,528
Medicare patients
392
Services billed
14,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$157,787
OzempicSemaglutide126$140,838
Repatha SureclickEvolocumab115$130,444
MounjaroTirzepatide104$121,882
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$93,808
JardianceEmpagliflozin66$89,136
XareltoRivaroxaban51$61,570
TrulicityDulaglutide28$36,255
MyrbetriqMirabegron45$28,151
Breo ElliptaFluticasone/Vilanterol37$27,662
FarxigaDapagliflozin Propanediol33$27,374
GemtesaVibegron34$22,936
LinzessLinaclotide32$20,533
JanuviaSitagliptin Phosphate15$19,088
Tresiba Flextouch U-200Insulin Degludec29$17,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$865$174,935170 claims
Lilly USA, LLCMounjaro, Trulicity$397$158,137132 claims
Novo NordiskOzempic$975$140,838126 claims
GSKTrelegy Ellipta, Breo Ellipta$605$121,470165 claims
Boehringer IngelheimJardiance$50$89,13666 claims
Johnson & JohnsonXarelto$172$61,57051 claims
AbbVieLinzess, Qulipta, Synthroid$875$42,084110 claims
AstraZenecaFarxiga, Breztri Aerosphere$52$38,42451 claims
Astellas Pharma US IncMyrbetriq$714$28,15145 claims
Sumitomo Pharma America, Inc.Gemtesa$149$22,93634 claims
MerckJanuvia$651$19,08815 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$78$13,15411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Punta Gorda

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →